Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arr… Read more
Solara Active Pharma Sciences Limited (SOLARA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.059x
Based on the latest financial reports, Solara Active Pharma Sciences Limited (SOLARA) has a cash flow conversion efficiency ratio of 0.059x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹740.70 Million) by net assets (₹12.57 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Solara Active Pharma Sciences Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Solara Active Pharma Sciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Solara Active Pharma Sciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Solara Active Pharma Sciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gesher Acquisition Corp. II
NASDAQ:GSHR
|
-0.001x |
|
Goldiam International Limited
NSE:GOLDIAM
|
-0.029x |
|
Sang-A Frontec Co.Ltd
KQ:089980
|
0.031x |
|
Risuntek Inc
SHE:002981
|
0.022x |
|
Greene County Bancorp Inc
NASDAQ:GCBC
|
0.025x |
|
ACQ BURE AB
F:0FE
|
N/A |
|
Dongwon F & B
KO:049770
|
0.026x |
|
Zhubo Design
SHE:300564
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Solara Active Pharma Sciences Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Solara Active Pharma Sciences Limited from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹10.97 Billion | ₹2.13 Billion | 0.194x | +66.91% |
| 2024-03-31 | ₹9.37 Billion | ₹1.09 Billion | 0.116x | +11.78% |
| 2023-03-31 | ₹15.02 Billion | ₹1.56 Billion | 0.104x | +165.95% |
| 2022-03-31 | ₹15.35 Billion | ₹-2.42 Billion | -0.158x | -261.57% |
| 2021-03-31 | ₹15.93 Billion | ₹1.55 Billion | 0.098x | -56.43% |
| 2020-03-31 | ₹10.90 Billion | ₹2.44 Billion | 0.224x | +34.55% |
| 2019-03-31 | ₹9.60 Billion | ₹1.60 Billion | 0.166x | +159.91% |
| 2018-03-31 | ₹7.68 Billion | ₹492.23 Million | 0.064x | -100.00% |
| 2017-03-31 | ₹67.00K | ₹492.23 Million | 7346.716x | -- |